Protocol Ledger

NCT06382155 · Phase II · RECRUITING

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

Interventional Phase II clinical trial protocol NCT06382155 sponsored by BioMarin Pharmaceutical in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-21 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06382155
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06382155
Protocol FieldVerified Registry Value
NCT IdentifierNCT06382155
Consolidated Lead SponsorBioMarin Pharmaceutical
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2024-10-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06382155
Hospital Research SiteLocationSite Profile
Children's Hospital Los AngelesLos Angeles, CAOpen Hospital Dossier ->
Nicklaus Children's HospitalMiami, FLOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for BioMarin Pharmaceutical across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI